Axon Enterprise, Inc (NASDAQ:AXON) Given Average Rating of “Moderate Buy” by Brokerages

Axon Enterprise, Inc (NASDAQ:AXON) has been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $721.5714.

AXON has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Argus raised their target price on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. The Goldman Sachs Group reiterated a “buy” rating and issued a $715.00 price target on shares of Axon Enterprise in a research note on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, July 22nd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, September 2nd.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $452.06 on Thursday. The stock has a market cap of $36.73 billion, a PE ratio of 187.58, a P/E/G ratio of 8.43 and a beta of 1.40. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise has a twelve month low of $339.01 and a twelve month high of $792.16. The stock has a fifty day simple moving average of $545.60 and a 200-day simple moving average of $485.63.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.84 by $0.04. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.12 EPS. Equities analysts anticipate that Axon Enterprise will post 2.12 earnings per share for the current year.

Insider Activity

In related news, insider Isaiah Fields sold 1,017 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $480.45, for a total value of $488,617.65. Following the transaction, the insider directly owned 56,264 shares of the company’s stock, valued at $27,032,038.80. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $574.43, for a total value of $9,636,063.25. Following the completion of the sale, the president directly owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This trade represents a 5.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,397 shares of company stock valued at $38,160,884 in the last 90 days. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in the stock. Pure Financial Advisors LLC boosted its holdings in shares of Axon Enterprise by 6.7% during the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 23 shares during the last quarter. Keel Point LLC increased its stake in shares of Axon Enterprise by 4.4% during the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 25 shares during the last quarter. Bridgewater Advisors Inc. increased its position in Axon Enterprise by 4.4% during the second quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. boosted its holdings in shares of Axon Enterprise by 2.4% in the 1st quarter. Roman Butler Fullerton & Co. now owns 1,278 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 30 shares during the last quarter. Finally, 44 Wealth Management LLC boosted its holdings in shares of Axon Enterprise by 6.0% in the 1st quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 30 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.